Fujifilm (OTCMKTS:FUJIY) Shares Gap Up - Here's What Happened

Key Points

• Fujifilm shares gapped up from a previous close of $10.70 to open at $11.10, with the last traded price at $10.63.
• Wall Street analysts downgraded Fujifilm from a "buy" rating to a "hold" rating on May 23rd.
• The company reported $0.22 EPS for the last quarter, exceeding the analysts' consensus estimate of $0.18 EPS.
• Fujifilm's market cap stands at $26.44 billion with a low debt-to-equity ratio of 0.14.

Fujifilm Holdings Corp. (OTCMKTS:FUJIY - Get Free Report) shares gapped up before the market opened on Friday . The stock had previously closed at $10.70, but opened at $11.10. Fujifilm shares last traded at $10.63, with a volume of 71,260 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen lowered shares of Fujifilm from a "buy" rating to a "hold" rating in a report on Friday, May 23rd.

Fujifilm Stock Performance

The company has a current ratio of 1.40, a quick ratio of 0.92 and a debt-to-equity ratio of 0.14. The firm's 50-day moving average is $10.71 and its two-hundred day moving average is $10.39. The stock has a market cap of $26.44 billion, a price-to-earnings ratio of 9.49, a P/E/G ratio of 2.92 and a beta of 0.67.

Fujifilm (OTCMKTS:FUJIY - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The technology company reported $0.22 EPS for the quarter, beating analysts' consensus estimates of $0.18 by $0.04. Fujifilm had a net margin of 8.15% and a return on equity of 7.84%. The company had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $822.51 billion. As a group, sell-side analysts expect that Fujifilm Holdings Corp. will post 0.66 earnings per share for the current year.

About Fujifilm

FUJIFILM Holdings Corporation develops, manufactures, sells, and services imaging, healthcare, materials, and business innovation solutions worldwide. The company's Healthcare segment provides products and services, such as medical devices, biomedical contract development and manufacturing organization, pharmaceutical, regenerative medicine, and cosmetics and supplements in the areas of prevention, diagnosis, and treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.